Integrating Functional Protein Drug Target Data into a Precision Oncology Molecular Tumor Board

Allison L. Hunt,Jaime Randall,Mahesh M Mansukhani,Kara Nyberg,Aratara Nutcharoen,Justin Davis,Brian Corgiat,Claudius Mueller,Savannah Melvin,Meenakshi Sharma,Laura Johnston,Whitney Swain,Tamara Abulez,Nicholas W. Bateman,George Larry Maxwell,John Deeken,Amin Benyounes,Emanuel Petricoin,Timothy L. Cannon,Thomas Conrads

DOI: https://doi.org/10.1101/2024.10.17.24315608

2024-10-18

Abstract:Collaborative review of molecular profiling data by multidisciplinary molecular tumor boards (MTB) is increasingly important for improving patient management and outcomes, though currently relies nearly exclusively on nucleic acid next-generation sequencing (NGS) and limited panels of immunohistochemistry-based protein abundance data. We examined the feasibility of incorporating real-time laser microdissection (LMD) enrichment of tumor epithelium and commercial CLIA-based reverse phase protein array (RPPA) protein drug target expression/activation profiling into our cancer center MTB to complement standard clinical NGS-based profiling. The LMD-RPPA workflow was performed within a therapeutically permissive timeframe with a median dwell time of nine days, during which specimens were processed outside of standard clinical workflows. The RPPA-generated data supported additional and/or alternative therapeutic considerations for 54% of profiled patients following review by the MTB. These findings suggest that integrating proteomic/phosphoproteomic and NGS-based genomic data creates opportunities to further personalize clinical decision-making for precision oncology.

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is that currently, Molecular Tumor Boards (MTBs) in cancer treatment decision - making mainly rely on genomics and transcriptomics data. However, the association between these data and protein activity and abundance is rather loose and cannot fully reflect the real state of drug targets. Specifically, the paper explores how to supplement the standard clinical NGS - based molecular profiling by integrating real - time Laser Micro - dissection (LMD) - enriched tumor epithelial cells and commercially CLIA - certified Reverse Phase Protein Array (RPPA) technology, in order to improve the precision and effectiveness of personalized medical decision - making.

The paper solves this problem through the following methods:
1. **Feasibility assessment of multi - omics workflow**: The research team first evaluated the feasibility of integrating the LMD - RPPA workflow into MTB discussions, ensuring that this process can be completed within the clinically allowed time. That is, the median time from the patient's consent to participate in the study to obtaining the RPPA report was 41 days, and the median processing time for the LMD - RPPA part was 9 days.
2. **Clinical application of proteomics data**: The research team conducted a comprehensive analysis of multi - omics data from 101 patients. The results showed that RPPA - based proteomics data supported additional or alternative treatment regimens for 54.5% of the patients. This indicates that proteomics data can provide important information beyond genomics and immunohistochemistry (IHC) data, which is helpful for more precise treatment method selection.
3. **Case analysis**: The paper mentioned several specific cases. For example, in a patient diagnosed with ALK - positive inflammatory myofibroblastic tumor, the RPPA data showed that the ALK signal was not activated, suggesting that the continued use of ALK inhibitors may be ineffective. Another triple - negative breast cancer patient, although IHC showed HER2 - negative, the RPPA data showed significant expression of HER2 and its phosphorylated form, supporting the use of HER2 - targeted therapy, and finally the patient had a complete response to this treatment.

In conclusion, by integrating proteomics data, this paper aims to provide MTBs with a more comprehensive molecular map, thereby optimizing treatment decisions for patients with advanced solid tumors and improving treatment outcomes.